Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RCP-AAV
- Development stage
- Preclinical
- Lead developer
- Ibex Biosciences
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
RCP-AAV is an investigational adeno-associated virus (AAV)-based gene therapy being developed by Ibex Biosciences for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a condition formerly known as non-alcoholic steatohepatitis (NASH). The therapy is designed to utilize an AAV vector to deliver a therapeutic transgene to hepatic cells to address the underlying drivers of liver inflammation and fibrosis associated with MASH. While the program is featured in Ibex Biosciences' pipeline, specific details regarding the molecular target, the transgene sequence, and the current clinical phase have not been publicly disclosed.
Beyond the preview
Go deeper on RCP-AAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RCP-AAV.